Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 8/20 | 0.63 |
| ▸ | MEN1 | O00255 | 7/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.63 |
| ▸ | CYP1A1 | P04798 | 6/20 | 0.63 |
| ▸ | CYP1B1 | Q16678 | 6/20 | 0.63 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.63 |
| ▸ | MAPT | P10636 | 5/20 | 0.63 |
| ▸ | CA12 | O43570 | 4/20 | 0.63 |
| ▸ | SLCO2B1 | O94956 | 4/20 | 0.63 |
| ▸ | PSMB5 | P28074 | 4/20 | 0.63 |
| ▸ | CA7 | P43166 | 4/20 | 0.63 |
| ▸ | TP53 | P04637 | 4/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.63 |
| ▸ | RECQL | P46063 | 4/20 | 0.63 |
| ▸ | AKR1B1 | P15121 | 4/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quercetin SCHEMBL4436805 | 0.99 | CYP3A4 (0.62) | CYP3A4MEN1KMT2AHSD17B10CYP1A2 | |
| Quercetin SCHEMBL10335403 | 0.84 | MEN1 (0.62) | CYP3A4MEN1KMT2AHSD17B10CYP1A2 | |
| Naringenin SCHEMBL6073059 | 0.82 | BACE1 (0.70) | CYP3A4MEN1KMT2AHSD17B10CYP1A2 | |
| Naringenin SCHEMBL28072458 | 0.82 | BACE1 (0.70) | CYP3A4MEN1KMT2AHSD17B10CYP1A2 | |
| Naringenin SCHEMBL28072460 | 0.82 | BACE1 (0.70) | CYP3A4MEN1KMT2AHSD17B10CYP1A2 | |
| Quercetin SCHEMBL288466 | 0.81 | MEN1 (0.92) | CYP3A4MEN1KMT2AHSD17B10CYP1A2 | |
| Quercetin SCHEMBL19723 | 0.79 | MEN1 (1.00) | CYP3A4MEN1KMT2AHSD17B10CYP1A2 | |
| Naringenin SCHEMBL1048136 | 0.79 | CYP19A1 (1.00) | CYP3A4MEN1KMT2AHSD17B10CYP1A2 | |
| Quercetin SCHEMBL17629824 | 0.79 | MEN1 (1.00) | CYP3A4MEN1KMT2AHSD17B10CYP1A2 | |
| Naringenin SCHEMBL20571 | 0.79 | CYP19A1 (1.00) | CYP3A4MEN1KMT2AHSD17B10CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2508182-B1 | Hydralazine for use in the treatment of age-related macular degeneration | TEXAS A & M UNIV SYS (US) | 2016-07-06 | — | — | EP | disclosed |
| EP-2508183-B1 | Interleukin-1 blocker for use in the treatment of age-related macular degeneration | TEXAS A & M UNIV SYS (US) | 2014-07-09 | — | — | EP | disclosed |
| US-20130059841-A1 | THERAPEUTIC COMPOSITIONS AND METHODS | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2013-03-07 | — | — | US | disclosed |
| US-8318741-B2 | Therapeutic compositions and methods | THE TEXAS A & M UNIVERSITY SYSTEM (US) | 2012-11-27 | — | — | US | disclosed |
| EP-2508182-A1 | Hydralazine for use in the treatment of age-related macular degeneration | THE TEXAS A & M UNIVERSITY SYSTEM (US) | 2012-10-10 | — | — | EP | disclosed |
| EP-2508183-A1 | Interleukin-1 blocker for use in the treatment of age-related macular degeneration | THE TEXAS A & M UNIVERSITY SYSTEM (US) | 2012-10-10 | — | — | EP | disclosed |
| US-20120196868-A1 | THERAPEUTIC COMPOSITIONS AND METHODS | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2012-08-02 | — | — | US | disclosed |
| US-20120115959-A1 | Therapeutic Compositions And Methods | THE TEXAS A&M UNIVERSITY SYSTEM | 2012-05-10 | — | — | US | disclosed |
| US-20120071485-A1 | Therapeutic Compositions And Methods | THE TEXAS A&M UNIVERSITY SYSTEM | 2012-03-22 | — | — | US | disclosed |
| US-8088773-B2 | Therapeutic compositions and methods | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2012-01-03 | — | — | US | disclosed |
| EP-1885371-A1 | THERAPEUTIC COMPOSITIONS AND METHODS | The Texas A & M University System (US) | 2008-02-13 | — | — | EP | disclosed |
| US-20060276458-A1 | Therapeutic compositions and methods | THE TEXAS A & M UNIVERSITY SYSTEM | 2006-12-07 | — | — | US | disclosed |
| WO-2006124324-A1 | THERAPEUTIC COMPOSITIONS AND METHODS | THE TEXAS A & M UNIVERSITY SYSTEM (US) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276458-A1 | Therapeutic compositions and methods | PDE6H, PDE6C, PDE6D | CYP3A4 4849/4885MEN1 2478/4885KMT2A 4122/4885 |
| US-20120115959-A1 | Therapeutic Compositions And Methods | PDE6C, PDE6H, PDE6D | CYP3A4 4835/4885MEN1 3145/4885KMT2A 3570/4885 |
| US-20120071485-A1 | Therapeutic Compositions And Methods | PDE6H, PDE6C, PDE6D | CYP3A4 4849/4885MEN1 2478/4885KMT2A 4122/4885 |
| US-20120196868-A1 | THERAPEUTIC COMPOSITIONS AND METHODS | PDE6H, PDE6C, PDE6D | CYP3A4 4849/4885MEN1 2478/4885KMT2A 4122/4885 |
| US-20130059841-A1 | THERAPEUTIC COMPOSITIONS AND METHODS | PDE6H, PDE6C, PDE6D | CYP3A4 4849/4885MEN1 2478/4885KMT2A 4122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.